Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4333829 | 0.86 | TYMP (0.39) | TYMP | |
| SCHEMBL7714333 | 0.84 | CDK5 (0.30) | — | |
| SCHEMBL313848 | 0.83 | TYMP (0.36) | TYMP | |
| SCHEMBL7202672 | 0.76 | TYMP (0.32) | TYMP | |
| SCHEMBL6066317 | 0.76 | TYMP (0.32) | TYMP | |
| SCHEMBL6895651 | 0.74 | AHCY (0.35) | — | |
| SCHEMBL2108084 | 0.74 | HPGD (0.38) | TYMP | |
| SCHEMBL6898692 | 0.74 | AHCY (0.35) | — | |
| SCHEMBL2109084 | 0.74 | TRDMT1 (0.36) | TYMP | |
| SCHEMBL2107681 | 0.74 | HPGD (0.37) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765701-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8697663-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120184031-A1 | ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA | ISIS PHARMACEUTICALS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-8178506-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8133876-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs | Regulus Therapeutics Inc. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20120035248-A9 | METHOD FOR INHIBITING THE ACTIVITY OF MIR-155 | REGULUS THERAPEUTICS, LLC. (US) | 2012-02-09 | — | — | US | disclosed |
| US-8110558-B2 | Oligomeric compounds and compositions for use in modulation of small non-coding RNAS | Regulus Therapeutics Inc. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8106025-B2 | Method for inhibiting the activity of mir-155 | Regulus Therapeutics Inc. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20110224277-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2332955-A2 | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression | ISIS Pharmaceuticals, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100267813-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100035964-A1 | ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20090317907-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090298174-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090291906-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090291907-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090286969-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | REGULUS THERAPEUTICS, LLC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090124009-A1 | ANTISENSE MODULATION OF PTP1B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20040102402-A1 | Modulation of tissue factor expression | ISIS PHARMACEUTICALS INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035248-A9 | METHOD FOR INHIBITING THE ACTIVITY OF MIR-155 | SYNCRIP, SNRPE, NSUN3 | TYMP 3842/4885 |
| US-20090291907-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | TYMP 3885/4885 |
| US-20090124009-A1 | ANTISENSE MODULATION OF PTP1B EXPRESSION | PPP3CA, PTPRJ, PPP2CA | TYMP 182/4885 |
| US-20090291906-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | TYMP 3885/4885 |
| US-20110224277-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | TYMP 3885/4885 |
| US-20090286969-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | TYMP 3885/4885 |
| US-20100267813-A1 | Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs | SNRPE, NSUN2, NSUN3 | TYMP 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.